by Editorial Team | 17 May, 2023 | LinkedIn, NEWS, TheraPPI
May 17, 2023 “”We are honoured to have been selected Tech Tour among innovative companies to present in Paris on 1st and 2nd June at FTI 2023. This is an exciting opportunity to present TheraPPI.” said Luc Otten Chief Executive Officer of TheraPPI...
by Editorial Team | 12 Apr, 2023 | LinkedIn, NEWS, TheraPPI
April 12, 2023 “”We’re are proud to be among the Finalists of the 2023 >>venture>> Finalists! Venture.ch is a highly competitve challenge for startups and selects highly promising start-ups.” said Luc Otten Chief Executive Officer of...
by Editorial Team | 28 Mar, 2023 | Netris, NEWS
March 28th, 2023 Lyon — NETRIS Pharma, a clinical-stage private biopharmaceutical company developing a new class of drugs based on dependence receptor biology, today announced dosing of the first patients in a multicenter, prospective, single arm, proof-of-concept...
by Editorial Team | 14 Mar, 2023 | Mablink, NEWS
March 14, 2023 – Lyon, France Mablink Bioscience (“Mablink”), a biotechnology company dedicated to advancing cancer therapy with next-generation antibody-drug conjugates (ADCs), today announced that preclinical efficacy and safety data on its lead ADC...
by Editorial Team | 26 Jan, 2023 | Netris, NEWS
Liver-NET1 study will evaluate safety and efficacy of anti-netrin-1 antibody NP137 in combination with Atezo-bev for first line patients with advanced HCC January 26th, 2023 Lyon — NETRIS Pharma, a clinical-stage private biopharmaceutical company developing a new...